Regeneron Pharma Q4 Results Top Estimates - Update

RTTNews | 569 dias atrás
Regeneron Pharma Q4 Results Top Estimates - Update

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.37 billion or $11.86 per share, compared to $1.45 billion or $12.56 per share in the year-ago quarter.

On average, 21 analysts polled by Thomson Reuters expected the company to report earnings of $10.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter edged up 1 percent to $3.43 billion from $3.41 billion in the same quarter last year. Excluding Ronapreve, revenue grew 14 percent. Analysts were looking for revenues of $3.29 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Marcadores : REGN
read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | 388 dias atrás
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | 422 dias atrás
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | 1150 dias atrás
Australian Market Slashes Early Gains In Mid-market

Australian Market Slashes Early Gains In Mid-market

The Australian stock market is slashing its early gains in mid-market trading on Monday, recouping the losses in the previous session, following the broadly positive cues from Wall Street on Friday. The benchmark S&P/ASX 200 index is moving up to near the 9,000.00 mark, with gains across most sectors led by mining and technology stocks. Financial stocks were the only weak spot.
RTTNews | 1h 6min atrás
Asian Markets Track Wall Street Higher

Asian Markets Track Wall Street Higher

Asian stock markets are trading mostly higher on Monday, following the broadly positive cues from Wall Street on Friday, on an improved outlook for interest rates after US Fed Chair Jerome Powell's dovish comments at the conference in Jackson Hole on Friday. Powell said economic risks are 'shifting' and a rate cut may be warranted. Asian markets closed mixed on Friday.
RTTNews | 1h 22min atrás
Thai Shares Tipped To Open To The Upside On Monday

Thai Shares Tipped To Open To The Upside On Monday

The Thai stock market has finished higher in two of three trading days since the end of the four-day losing streak in which it had slumped more than 40 points or 3.5 percent. The Stock Exchange of Thailand now sits just above the 1,250-point plateau and it's poised to extend its gains on Monday.
RTTNews | 2h 32min atrás